PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT • 2.1 Preface • 2.2 Preface • 2.3 Currency conversion rates for US$ PART 03: MARKET LANDSCAPE • Market ecosystem • Market characteristics • Market segmentation analysis PART 04: MARKET SIZING • Market definition • Market sizing 2018 • Market size and forecast 2018-2023 PART 05: FIVE FORCES ANALYSIS • Bargaining power of buyers • Bargaining power of suppliers • The threat of new entrants • Threat of substitutes • Threat of rivalry • Market condition PART 06: MARKET SEGMENTATION BY PRODUCT • Market segmentation by product • Comparison by product • RTKIs - Market size and forecast 2018-2023 • nRTKIs - Market size and forecast 2018-2023 • Market opportunity by product PART 07: CUSTOMER LANDSCAPE PART 08: GEOGRAPHIC LANDSCAPE • Geographic segmentation • Geographic comparison • Americas - Market size and forecast 2018-2023 • EMEA - Market size and forecast 2018-2023 • APAC - Market size and forecast 2018-2023 • Key leading countries • Market opportunity PART 09: DRIVERS AND CHALLENGES • Market drivers • Market challenges PART 10: MARKET TRENDS PART 11: VENDOR LANDSCAPE • Overview • Landscape disruption • Competitive scenario PART 12: VENDOR ANALYSIS • Vendors covered • Vendor classification • Market positioning of vendors • Bristol-Myers Squibb • F. Hoffmann-La Roche • Johnson & Johnson • Novartis • Pfizer PART 13: APPENDIX • Research methodology • List of abbreviations Exhibit 02: Global pharmaceuticals market Exhibit 03: Segments of global pharmaceuticals market Exhibit 04: Market characteristics Exhibit 05: Market segments Exhibit 06: Market definition - Inclusions and exclusions checklist Exhibit 07: Market size 2018 Exhibit 08: Global market: Size and forecast 2018-2023 ($ billions) Exhibit 09: Global market: Year-over-year growth 2019-2023 (%) Exhibit 10: Five forces analysis 2018 Exhibit 11: Five forces analysis 2023 Exhibit 12: Bargaining power of buyers Exhibit 13: Bargaining power of suppliers Exhibit 14: Threat of new entrants Exhibit 15: Threat of substitutes Exhibit 16: Threat of rivalry Exhibit 17: Market condition - Five forces 2018 Exhibit 18: Product - Market share 2018-2023 (%) Exhibit 19: Comparison by product Exhibit 20: RTKIs - Market size and forecast 2018-2023 ($ billions) Exhibit 21: RTKIs - Year-over-year growth 2019-2023 (%) Exhibit 22: nRTKIs - Market size and forecast 2018-2023 ($ billions) Exhibit 23: nRTKIs - Year-over-year growth 2019-2023 (%) Exhibit 24: Market opportunity by product Exhibit 25: Customer landscape Exhibit 26: Market share by geography 2018-2023 (%) Exhibit 27: Geographic comparison Exhibit 28: Americas - Market size and forecast 2018-2023 ($ billions) Exhibit 29: Americas - Year-over-year growth 2019-2023 (%) Exhibit 30: Top 3 countries in Americas Exhibit 31: EMEA - Market size and forecast 2018-2023 ($ billions) Exhibit 32: Example of patient-assistance program for cancer treatment Exhibit 33: EMEA - Year-over-year growth 2019-2023 (%) Exhibit 34: Top 3 countries in EMEA Exhibit 35: APAC - Market size and forecast 2018-2023 ($ billions) Exhibit 36: APAC - Year-over-year growth 2019-2023 (%) Exhibit 37: Top 3 countries in APAC Exhibit 38: Key leading countries Exhibit 39: Market opportunity Exhibit 40: Decision framework Exhibit 41: Reported top 5 new cases of cancer types in US in 2015 Exhibit 01: Treatment costs of TKIs Exhibit 02: Side effects of TKIs Exhibit 03: Impact of drivers and challenges Exhibit 07: Vendor landscape Exhibit 08: Landscape disruption Exhibit 09: Vendors covered Exhibit 10: Vendor classification Exhibit 11: Market positioning of vendors Exhibit 12: Bristol-Myers Squibb - Vendor overview Exhibit 13: Bristol-Myers Squibb - Business segments Exhibit 14: Bristol-Myers Squibb - Organizational developments Exhibit 15: Bristol-Myers Squibb - Geographic focus Exhibit 16: Bristol-Myers Squibb - Key offerings Exhibit 17: Bristol-Myers Squibb - Key customers Exhibit 18: F. Hoffmann-La Roche - Vendor overview Exhibit 19: F. Hoffmann-La Roche - Business segments Exhibit 20: F. Hoffmann-La Roche - Organizational developments Exhibit 21: F. Hoffmann-La Roche - Geographic focus Exhibit 22: F. Hoffmann-La Roche - Segment focus Exhibit 23: F. Hoffmann-La Roche - Key offerings Exhibit 24: F. Hoffmann-La Roche - Key customers Exhibit 25: Johnson & Johnson - Vendor overview Exhibit 26: Johnson & Johnson - Business segments Exhibit 27: Johnson & Johnson - Organizational developments Exhibit 28: Johnson & Johnson - Geographic focus Exhibit 29: Johnson & Johnson - Segment focus Exhibit 30: Johnson & Johnson - Key offerings Exhibit 31: Johnson & Johnson - Key customers Exhibit 32: Novartis - Vendor overview Exhibit 33: Novartis - Business segments Exhibit 34: Novartis - Organizational developments Exhibit 35: Novartis - Geographic focus Exhibit 36: Novartis - Segment focus Exhibit 37: Novartis - Key offerings Exhibit 38: Novartis - Key customers Exhibit 39: Pfizer - Vendor overview Exhibit 40: Pfizer - Business segments Exhibit 41: Pfizer - Organizational developments Exhibit 42: Pfizer - Geographic focus Exhibit 43: Pfizer - Segment focus Exhibit 44: Pfizer - Key offerings Exhibit 45: Pfizer - Key customers Exhibit 46: Validation techniques employed for market sizing Exhibit 47: List of abbreviations  

Bristol-Myers Squibb F. Hoffmann-La Roche Johnson & Johnson Novartis Pfizer